Get the latest Science News and Discoveries
Case Western Reserve University receives $1.5 - EurekAlert
There’s only one U.S. Food and Drug Administration-approved therapy for an inherited retinal disease, and dozens of retinitis pigmentosa (RP) genes for which no therapy is available. With a new three-year, $1.5 million grant from the Foundation Fighting Blindness, Shigemi Matsuyama, an associate professor of ophthalmology and visual sciences at the Case Western Reserve University School of Medicine, will test a possible breakthrough drug that can be taken by mouth—one that may address many RP disease manifestations, regardless of the underlying genetic mutation.
None
Or read this on Eureka Alert